NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球5-HT3受體拮抗劑市場:2021∼2028年

Global 5HT3 Receptor Antagonists Market - 2021-2028

出版商 DataM Intelligence 商品編碼 1024555
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
全球5-HT3受體拮抗劑市場:2021∼2028年 Global 5HT3 Receptor Antagonists Market - 2021-2028
出版日期: 2021年08月20日內容資訊: 英文 180 Pages
簡介

5-HT3受體拮抗劑,用某種的大腸激躁症的治療,及緩和噁心、嘔吐所採用的藥物的一種,是制吐劑。預計癌症的盛行率上升將帶動該市場的成長。

本報告提供全球5-HT3受體拮抗劑市場相關調查,市場概要,以及各產品類型,各用途,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 全球5-HT3受體拮抗劑市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球5-HT3受體拮抗劑市場-市場定義和概要

第3章 全球5-HT3受體拮抗劑市場-摘要整理

  • 各產品類型的市場明細
  • 各用途的市場明細
  • 各地區的市場明細

第4章 全球5-HT3受體拮抗劑市場-市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球5-HT3受體拮抗劑市場-產業分析

  • 波特的五力分析
  • 流行病學分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球5-HT3受體拮抗劑市場-COVID-19分析

  • 市場上的Covid-19分析
    • COVID-19前的市場方案
    • COVID-19目前市場方案
    • COVID-19後或未來方案
  • Covid-19的價格動態
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球5-HT3受體拮抗劑市場-各產品類型

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%),各產品類型
    • 市場魅力指數
  • 第一世代
    • Dolasetron
    • Granisetron
    • Ondansetron
    • 簡介
    • 市場規模分析,百萬美元,2019∼2028年,及與前一年同期比較成長分析(%),2020∼2028年
  • 第二世代
    • Palonosetron

第8章 全球5-HT3受體拮抗劑市場-各用途

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途
    • 市場魅力指數
  • CINV
    • 簡介
    • 市場規模分析,百萬美元,2019∼2028年,及與前一年同期比較成長分析(%),2020∼2028年
  • RINV
  • PONV

第9章 全球5-HT3受體拮抗劑市場-各地區

  • 簡介
    • 市場規模分析,百萬美元,2019∼2028年,及與前一年同期比較成長分析(%),2020∼2028年,各地區
    • 市場魅力指數
  • 北美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各產品類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 歐洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各產品類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 南美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各產品類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 亞太地區
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各產品類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 中東和非洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各產品類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各用途

第10章 全球5-HT3受體拮抗劑市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準
  • 值得注意的主要企業的清單
  • 顛覆性技術的企業的清單
  • Start-Ups企業的清單

第11章 全球5-HT3受體拮抗劑市場-企業簡介概要

  • Novartis Pharmaceuticals Corporation
    • 企業概要
    • 產品系列和概要
    • 主要的焦點
    • 財務概要
  • Heron Therapeutics, Inc.
  • GlaxoSmithKline plc
  • Eisai, Inc.
  • Helsinn Holding S.A.
  • Sanofi
  • Midatech Pharma US, Inc.
  • Kyowa Kirin, Inc.
  • Tesaro, Inc.
  • Merck & Co., Inc.

非詳細列表

第12章 全球5-HT3受體拮抗劑市場-DataM

  • 附錄
  • 關於我們
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMPH3916

5HT3 Receptor Antagonists Market Overview

The global 5HT3 receptor antagonists market size was valued US$ YY billion in 2020 and is estimated to reach US$ YY billion by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).

It is a type of drug used to treat certain types of irritable bowel syndrome and relieve nausea and vomiting. It is an antiemetic.

5HT3 Receptor Antagonists Market Dynamics

An increase in the prevalence of cancer is expected to drive the market's growth.

According to the Journal, it is estimated 54,010 adults (38,800 men and 15,210 women) in the United States will be diagnosed with oral and oropharyngeal cancer. Moreover, if the cancer is diagnosed early, all people's overall 5-year survival rate is 85%. About 29% of oral and oropharyngeal cancers are diagnosed at this stage. Additionally, if cancer has spread to surrounding tissues or organs or the regional lymph nodes, the overall 5-year survival rate is 67%, and almost half of cases are diagnosed at this stage. If cancer has spread to a distant part of the body, the overall 5-year survival rate is 40%. Most oropharyngeal cancers are caused by HPV infection, smoking or tobacco use and heavy alcohol consumption.

Therefore, antiemetic therapy is crucial for patients undergoing chemotherapy or radiotherapy for cancer. Severe nausea and vomiting associated with cancer treatment can lead to anxiety, anorexia, dehydration, electrolyte disturbance and renal failure. They may interrupt cancer therapy, demoralize patients or even cause them to abandon treatment. Several selective 5HT3-receptor antagonists are licensed(i.e.: ondansetron, the first selective serotonin type 3- (5HT3-) receptor antagonist). Thus increasing cases of cancer has driven the market in the forecast period.

Side-Effects Associated with the use of the drug are expected to hamper the market's growth.

According to the article, on Oct 26, 2020. Granisetron is used to prevent nausea and vomiting caused by surgery, cancer chemotherapy, or radiation treatment. Every drug has its benefits. It even has side effects, including diarrhea, constipation, stomach pain or upset, loss of appetite, weakness, headache, fever, dizziness, drowsiness, trouble sleeping (insomnia), and anxiety. Thus, from the above factors, the market is expected to hamper the market's growth in the forecast period.

COVID-19 Impact Analysis

The coronavirus disease 2019 pandemic has affected millions of people worldwide and severely disrupted the delivery of health care. Recent studies have demonstrated that patients with preexisting cardiovascular disease and cancer are at increased risk of infection and life-threatening complications due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, there has been a high prevalence of cardiovascular comorbidities among patients with COVID-19, particularly those with severe disease. Recent case series also report a significant increase in severe outcomes and case fatalities among patients with cancer with COVID-19. Based on these, cardio-oncology patients are likely to be particularly susceptible to poor outcomes from COVID-19 given their compromised immune system and limited cardiopulmonary reserve related to coexistent cancer and cardiovascular disease.

In addition, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. However, the situation is expected to improve gradually in the

forecast period.

5HT3 Receptor Antagonists Market Segment Analysis

Second generation segment is expected to hold the largest market share in this market segment.

The second-generation segment accounted for the largest market share in 2020. The segment's growth is benefited because the newer drug palonosetron is a pharmacologically distinct and highly selective, second-generation 5-HT3 receptor antagonist and has a longer half-life (40h) and greater receptor binding affinity. Moreover, it is used to prevent nausea and vomiting caused by cancer medicines (chemotherapy). It is used to prevent nausea and vomiting that may occur after surgery. It works by blocking the signals to the brain that cause nausea and vomiting. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

5HT3 Receptor Antagonists Market Geographical Analysis

North America region holds the largest market share in the global 5HT3 receptor antagonists market.

North America dominated the market and led to the largest revenue share in 2020. The region's growth is attributed to the ongoing technological advancement in the region. The presence of leading healthcare companies, raising cases of surgeries and the high prevalence of chronic diseases such as diabetes is expected to boost the market in the forecast period. For instance, according to the article, on 11 February 2021, diabetes is a serious and increasingly common chronic disease that can cause devastating complications that often result in disability and death. As early detection, improved delivery of care and better self-management are key strategies for preventing much of the burden of diabetes. Type 2 diabetes, formerly considered adult-onset diabetes, is now being diagnosed more commonly seen among children and adolescents. This type of diabetes is linked to two modifiable risk factors obesity and physical inactivity.

Moreover, 34.2 million Americans-just over 1 in 10-have diabetes, and 88 million American adults-approximately 1 in 3-have prediabetes. Newly diagnosed cases of type 1 and type 2 diabetes have significantly increased among US youth. For ages 10 to 19 years, the incidence of type 2 diabetes remained stable among non-Hispanic whites and increased for all others, especially non-Hispanic blacks. Thus, the region is expected to hold the largest market region in the forecast period from the above statements.

5HT3 Receptor Antagonists Market Competitive Landscape

The 5HT3 receptor antagonists market is vast with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include GlaxoSmithKline plc, Heron Therapeutics, Inc., Merck & Co., Inc., Eisai, Inc., Novartis Pharmaceuticals Corporation , Helsinn Holding S.A., Sanofi, Midatech Pharma US, Inc.,Kyowa Kirin, Inc. and Tesaro, Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the 5HT3 receptor antagonists market globally.

5HT3 Receptor Antagonists Market Key Companies to Watch

Novartis Pharmaceutical Company:

Overview:

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is a publicly-traded Swiss holding company that operates through the Novartis Group. Novartis AG owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group. Moreover, Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). It is one of the largest pharmaceutical companies in the world.

Product Portfolio:

Novartis Pharmaceutical Company has continuously set new standards for manufacturing of products including Zofran ODT® (ondansetron), and Zofran® (ondansetron hydrochloride).

Why Purchase the Report?

  • Visualize the composition of the 5HT3 receptor antagonists market segmentation by product type, application and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in 5HT3 receptor antagonists market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of 5HT3 receptor antagonists market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global 5HT3 receptor antagonists market report would provide an access to an approx.47 market data table, 39 figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global 5HT3 Receptor Antagonists Market - By Product Type

  • First Generation

Dolasetron

Granisetron

Ondansetron

  • Second Generation

Palonosetron

Global 5HT3 Receptor Antagonists Market - By Application

  • CINV
  • RINV
  • PONV

Global 5HT3 Receptor Antagonists Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Global 5HT3 Receptor Antagonists Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global 5HT3 Receptor Antagonists Market - Market Definition and Overview

3. Global 5HT3 Receptor Antagonists Market - Executive Summary

  • 3.1. Market Snippet by Product type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Global 5HT3 Receptor Antagonists Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. An increase in the prevalence of cancer is expected to drive the market's growth.
      • 4.1.1.2. The advancement of pharmaceutical and medical technologies is expected to drive the market's growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side-Effects Associated with the use of the drug are expected to hamper the market's growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global 5HT3 Receptor Antagonists Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global 5HT3 Receptor Antagonists Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global 5HT3 Receptor Antagonists Market - By Product type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 7.1.2. Market Attractiveness Index, By Product type Segment
  • 7.2. First Generation*
    • 7.2.1. Dolasetron
    • 7.2.2. Granisetron
    • 7.2.3. Ondansetron
    • 7.2.4. Introduction
    • 7.2.5. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Second Generation
    • 7.3.1. Palonosetron

8. Global 5HT3 Receptor Antagonists Market - By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. CINV*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. RINV
  • 8.4. PONV

9. Global 5HT3 Receptor Antagonists Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10. Global 5HT3 Receptor Antagonists Market - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking
  • 10.4. List of Key Companies to Watch
  • 10.5. List of Company with disruptive technology
  • 10.6. List of Start Up Companies

11. Global 5HT3 Receptor Antagonists Market- Company Profiles

  • 11.1. Novartis Pharmaceuticals Corporation*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Heron Therapeutics, Inc.
  • 11.3. GlaxoSmithKline plc
  • 11.4. Eisai, Inc.
  • 11.5. Helsinn Holding S.A.
  • 11.6. Sanofi
  • 11.7. Midatech Pharma US, Inc.
  • 11.8. Kyowa Kirin, Inc.
  • 11.9. Tesaro, Inc.
  • 11.10. Merck & Co., Inc.

LIST NOT EXHAUSTIVE

12. Global 5HT3 Receptor Antagonists Market - DataM

  • 12.1. Appendix
  • 12.2. About Us
  • 12.3. Contact Us